Fig. 2
From: Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
Kaplan–Meier analysis of overall survival (OS) in NSCLC patients according to the KRAS-mutation status
Fig. 2 | British Journal of Cancer
From: Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
Kaplan–Meier analysis of overall survival (OS) in NSCLC patients according to the KRAS-mutation status
